Carbonic Anhydrase Inhibitors in Oncology
Targeting acid-regulating proteins in tumors may enhance cancer treatments, particularly by combining with emerging strategies that damage cancer cell metabolism.
This comprehensive review covers CA IX and CA XII as tumor microenvironment pH regulators in hypoxic cancers, summarizing small molecule inhibitors (SLC-0111 through Phase I), dual-target inhibitors, antibody-based strategies, and ADC approaches. The review highlights novel mechanistic intersections with ferroptosis and redox biology as emerging rational polypharmacology targets.
What the study was
- Study design
- Narrative review
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Sub-Cellular Biochemistry
Why it surfaced
Comprehensive review of CA IX/XII inhibitors in oncology with Phase I clinical trial completion noted. Useful reference for precision oncology surveillance but no novel clinical data; review design limits score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.